BLUEPRINT MEDICINES CORP's ticker is BPMC and the CUSIP is 09627Y109. A total of 164 filers reported holding BLUEPRINT MEDICINES CORP in Q4 2018. The put-call ratio across all filers is 0.79 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $2,123,528 | -36.1% | 47,200 | -37.8% | 0.01% | -44.4% |
| Q4 2022 | $3,325,179 | -18.5% | 75,900 | +22.6% | 0.01% | -25.0% |
| Q3 2022 | $4,079,000 | -30.8% | 61,900 | -15.9% | 0.01% | -14.3% |
| Q4 2019 | $5,896,000 | -31.5% | 73,600 | -37.1% | 0.01% | -33.3% |
| Q3 2019 | $8,603,000 | -20.1% | 117,100 | +2.5% | 0.02% | -22.2% |
| Q2 2019 | $10,772,000 | +15.6% | 114,200 | -1.9% | 0.03% | +17.4% |
| Q1 2019 | $9,318,000 | +8.5% | 116,400 | -26.9% | 0.02% | 0.0% |
| Q4 2018 | $8,588,000 | -31.9% | 159,300 | -1.4% | 0.02% | -25.8% |
| Q3 2018 | $12,614,000 | -12.5% | 161,600 | -28.8% | 0.03% | -20.5% |
| Q2 2018 | $14,410,000 | +109.0% | 227,000 | +201.9% | 0.04% | +105.3% |
| Q1 2018 | $6,896,000 | +12.3% | 75,200 | -7.6% | 0.02% | +11.8% |
| Q4 2017 | $6,138,000 | +104.9% | 81,400 | +89.3% | 0.02% | +112.5% |
| Q3 2017 | $2,996,000 | +496.8% | 43,000 | +334.3% | 0.01% | +300.0% |
| Q2 2017 | $502,000 | +10.1% | 9,900 | -13.2% | 0.00% | +100.0% |
| Q1 2017 | $456,000 | – | 11,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 705,159 | $12,728,000 | 12.46% |
| BVF INC/IL | 2,640,251 | $47,657,000 | 11.79% |
| Casdin Capital, LLC | 321,300 | $5,799,000 | 6.66% |
| Opaleye Management Inc. | 220,000 | $3,971,000 | 2.48% |
| PFM Health Sciences, LP | 1,420,511 | $25,640,000 | 0.79% |
| Perceptive Advisors | 404,404 | $7,299,000 | 0.64% |
| Partner Investment Management, L.P. | 18,788 | $339,000 | 0.55% |
| Visium Asset Management, LP | 1,265,025 | $22,834,000 | 0.39% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 661,717 | $11,944,000 | 0.39% |
| Virtus ETF Advisers LLC | 10,484 | $189,000 | 0.26% |